Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Left Atrial Appendage Occlusion and Early Bleeding

Percutaneous left atrial appendage occlusion (LAAO) is presented as an alternative to chronic oral anticoagulation in patients with non-valvular atrial fibrillation. By isolating the left atrial appendage, it is possible to prevent the migration of thrombi associated with atrial fibrillation, which tend to appear in this region. However, since it involves an external device, there is a possibility of in-situ thrombus formation (device-related thrombus, DRT), which warrants intensive antithrombotic treatment during the endothelialization phase.

This initial phase is critical, especially in patients with a very high or prohibitive risk of bleeding. The objective of this study, presented by Mesnier et al., was to assess the incidence, predictors, and clinical consequences of early bleeding unrelated to the procedure.

The study included patients who underwent LAAO in nine centers across Europe and Canada between 2009 and 2021. Bleeding events were classified as life-threatening, major, or minor. Major bleeding included fatal bleeding, bleeding in critical organs, bleeding causing hypovolemic shock or a drop in hemoglobin of at least 3 g/dL, and bleeding requiring more than 2 units of red blood cells. “Early” was defined as occurring within the first 3 months after the procedure.

The primary endpoint (PE) was the occurrence of early bleeding unrelated to the procedure. The secondary endpoint (SE) included early major bleeding, all-cause mortality, DRT, ischemic stroke, and peripheral cardioembolic disease. DRT was defined as the presence of a thrombus attached to the left side of the device, as detected by tomography or transesophageal echocardiography.

Read also: DIRECT TAVI: Is Predilation Important for Women?

The number of patients who underwent LAAO and were included amounted to 1649. Early bleeding occurred in 7.3% of cases, of which 4.2% were major bleeding events, which accounted for 57% of all bleeding events.

Patients who experienced early bleeding tended to be older (77.5 ± 7.3 years vs. 75.8 ± 8.3 years; P=0.03), had a higher degree of renal failure (50.4% [61/121] vs. 36.8% [562/1528]; P=0.003), a history of coronary artery disease (46.3% [56/121] vs. 32.2% [492/1528]; P=0.002), and had experienced previous episodes of heart failure or some type of bleeding (94.2% [114/121] vs. 81.3% [1242/1528]; P<0.001). Among the latter, gastrointestinal bleeding was the most significant type (61.2% [74/121] vs. 34.4% [526/1528]; P<0.001).

In the multivariate model, factors associated with an increased risk of early post-procedural bleeding included the use of dual antiplatelet therapy (DAPT) (adjusted hazard ratio [aHR]: 1.61; 95% confidence interval [CI]: 1.12-2.33; P=0.01), prior gastrointestinal bleeding (aHR: 2.15; 95% CI: 1.38-3.35; P<0.001), and bleeding in other places (aHR: 2.33; 95% CI: 1.34-4.05; P<0.001).

Read also: EMPIRE Trial: Is Microvascular Protection Feasible in PCI Depending on the Stenting Technique?

After an average follow-up of 2.3 years, 33.3% of the patients died, and 50.3% of those deaths attributed to vascular causes. Early bleeding unrelated to the procedure was independently associated with an increase in all-cause mortality (aHR: 1.53; 95% CI: 1.15-2.06; P<0.001).

Conclusions

According to the results observed in these centers, early bleeding occurred in 7.3% of cases, with the use of DAPT being the only modifiable factor. Furthermore, the occurrence of bleeding significantly reduced the survival of these patients.

Original Title: Early Nonprocedural Bleeding After Left Atrial Appendage Occlusion.

Reference: Mesnier, J, Cruz-González, I, Guedeney, P. et al. Early Nonprocedural Bleeding After Left Atrial Appendage Occlusion. J Am Coll Cardiol Intv. 2024 Aug, 17 (15) 1765–1776. https://doi.org/10.1016/j.jcin.2024.05.032.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

Más artículos de este Autor

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Artículos relacionados

Jornadas Guatemala 2026
Jornadas SOLACIspot_img

Artículos recientes

06/03 | SOLACI Technicians & Nurses Webinar – Clinical Impact of Structural Interventions: TAVI and MitraClip in Current Practice

The Latin American Society of Interventional Cardiology (SOLACI), through its Technicians and Nurses Department, invites you to participate in a new scientific webinar entitled...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...